CALGB 40601 Alliance: impact of dual HER2 targeting on pCR

Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Breast CancerПодробнее

Genomic Analysis of CALGB 40601 for HER2-Positive Breast CancerПодробнее

The impact of biomarkers on pCR and survival in WSG ADAPT TPПодробнее

Treatment for HER2+ metastatic breast cancerПодробнее

Dr. Hamilton on Using pCR to Classify Risk in HER2+ Breast CancerПодробнее

Dr. Bardia on Dual Targeting of the HER2 ReceptorПодробнее

Optimising Treatment Selection for Patients with ER+/HER2- Breast CancerПодробнее

Dual HER2 blockade in patients with HER2-positive breast cancer after pCRПодробнее

Targeting HER2 by Combination TherapiesПодробнее

Association of pathologic complete response following neoadjuvant chemotherapy with longterm sur...Подробнее

Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast CancerПодробнее

HER2 Positive Breast Cancer ManagementПодробнее

Air Pollution Linked to Higher Rates of Head and Neck CancerПодробнее

Dr. Bhave on Promising Anti-HER2 Agents in HER2+ Breast CancerПодробнее

Immunotherapy research leads to big breakthroughs for prostate cancer patientsПодробнее

HER2 Testing in Gastroesophageal CancersПодробнее

Dr. Hudis Discusses the CALGB 40601 Study in Breast CancerПодробнее

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockadeПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее